← Scoopfeeds — Intelligent news, curated.
UBS reiterates Celldex Therapeutics stock rating on trial data
business

UBS reiterates Celldex Therapeutics stock rating on trial data

Investing.com · Jun 16, 2026, 2:15 PM · Also reported by 2 other sources

UBS reiterates Celldex Therapeutics stock rating on trial data

Read full story on Investing.com → More top stories

Also covered by

Yahoo Finance Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now? Yahoo Finance Why This AI Data Center Stock Is Surging 21% on an AMD Partnership

More in business

CNBC
Jim Cramer debates his next move on a software stock on an 11 day losing streak
Yahoo Finance
This Storage Stock Is Now Up More Than 700% in a Year, and the AI Boom Could Push It Even Higher.
Yahoo Finance
Aviva expands ChatGPT distribution channel
Yahoo Finance
I’ve been maxing out my after-tax 401(k) and converting it to a Roth for 2 years — is this a good strategy?
Yahoo Finance
AeroVironment’s newest weapon isn’t a drone
Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop